Angiosarcoma is a type of soft-tissue sarcoma that arises from the endothelial cells. The disease is generally aggressive and characterized by extensively infiltrating anaplastic and rapidly proliferating cells. Angiosarcoma can occur in any part of the body but it is mostly found in the skin and soft tissues. Head and neck angiosarcoma accounts for around 50% of the cases of angiosarcoma. Cutaneous angiosarcoma is a type of angiosarcoma which is mostly found in females whereas, in males, bone and soft tissue sarcoma is more common. Tracon Pharmaceuticals, Inc. is in the process of developing TRC105 as a ENG protein inhibitor for the treatment of angiosarcoma. Bayer AG is in the process of developing regorafenib as a multiple membrane-bound and intracellular kinases inhibitor for the treatment of angiosarcoma. Some of the companies and universities having the pipeline of angiosarcoma include Tracon Pharmaceuticals, Inc., Northwestern University, and others.
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.